UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s “sector-leading pipeline potential” for the upgrade.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca (AZN) Announces Q1 Dividend: Read On for Important Dates
- AstraZeneca’s Strong Financial Performance and Growth Projections Drive Positive Analyst Rating
- SpringWorks Therapeutics price target raised to $66 from $63 at TD Cowen
- AstraZeneca: Strong Growth Prospects and Transformative Clinical Trials Justify Buy Rating
- AstraZeneca initiated with an Overweight at Morgan Stanley